CDMRP Peer Reviewed Medical Research Program Focused Program Award | W81XWH 20 PRMRP FPA

Opportunity Information: Apply for W81XWH 20 PRMRP FPA

The CDMRP Peer Reviewed Medical Research Program (PRMRP) Focused Program Award (FPA) is a Department of Defense funding mechanism designed to push a research area forward faster by funding a coordinated, multi-project program rather than a single standalone study. The central idea is to accelerate answers and practical solutions to a high-impact, clearly defined problem that fits within at least one of the Congressionally directed FY20 PRMRP Topic Areas. Instead of supporting scattered efforts, this opportunity aims to create a deliberately structured portfolio of projects that work together in a way that produces more progress than the same projects would achieve if they were funded separately.

A defining requirement is the presence of a single unifying "overarching challenge." Applicants must frame their proposal around one critical question or urgent problem in research and/or patient care, and then show how the entire program is organized to solve it. The challenge cannot be vague or purely exploratory; it needs to be tied to a real bottleneck in the field and be directly relevant to the FY20 PRMRP topic space. Reviewers will be looking for a program-level story: what the major obstacle is, why it matters now, and why the proposed coordinated approach is the fastest and most credible way to overcome it.

To address that overarching challenge, applications must include multiple distinct research projects, each led by its own project leader. The program is expected to be substantial; applicants are strongly encouraged to include at least four research projects, though more are allowed. Each project must be scientifically strong on its own, but the key is synergy: the projects should be intentionally complementary, cover different angles or hypotheses, and connect in a way that produces an integrated solution. The solicitation explicitly encourages exploring multiple hypotheses or viewpoints around the same general question, but it discourages "domino-chain" designs where later projects depend on earlier projects succeeding. In other words, the program should be resilient and productive even if one component hits a setback, with each project still capable of generating meaningful, field-relevant results.

The scientific scope is broad across the translational pipeline. Individual projects may range from early exploratory or hypothesis-generating work all the way to small-scale clinical trials, including up to Phase II (or equivalent). Even when early-stage science is included, the program should show a clear intent to move toward translational or clinical application over the life of the award. This emphasis reflects the program's purpose: not just generating knowledge, but moving toward outcomes that can realistically influence future research directions, clinical practice, or patient care.

A major part of the application is the implementation plan, which is treated as a serious management and execution roadmap rather than a simple timeline. Applicants are expected to lay out critical milestones, explain what resources and technical innovations will be used to reach those milestones, and provide a credible approach for tracking progress at both the project level and the program level (meaning progress toward solving the overarching challenge). Where applicable, the program expects a robust statistical plan and demonstrated statistical expertise, signaling that rigor and reproducibility are priorities. Applicants are also encouraged to propose an External Advisory Board to strengthen guidance and accountability, but they must avoid conflicts of interest during peer review by not contacting, recruiting, or naming specific individuals in the application.

Because these programs often involve multiple institutions, the opportunity places clear expectations on coordination and governance. Multi-institutional applications must describe how the team will communicate, how data will be transferred securely and efficiently, and how any shared assets such as datasets, specimens, or study products will be handled across sites. In addition, the application must include an intellectual and material property plan that is agreed to by all participating organizations and included in the supporting documentation. This requirement signals that the DoD expects teams to resolve collaboration and ownership issues up front so the science is not delayed later by administrative disputes.

Leadership and team structure are central to this mechanism. The overall program is led by a Principal Investigator who has proven experience managing large, focused efforts and who can actively drive collaboration across disciplines. The PI must commit at least 20 percent effort to the award, reinforcing that this is not meant to be lightly supervised. The PI is expected to build a team culture that promotes genuine integration, with project leaders who bring distinct expertise that collectively forms a multidisciplinary, highly capable collaboration. The program also anticipates active engagement with DoD program oversight: the PRMRP Science Officer assigned to the award should be invited to research team meetings (such as annual full-team meetings), and the plan for those interactions should be included in the proposal.

There is also a formal accountability checkpoint built into the award. After Year 2, the PI is required to present a progress update at a Milestone Meeting held in the National Capital Area. The PI may bring up to three additional team members. This meeting will include the PRMRP Programmatic Panel, CDMRP staff, the USAMRAA Grants Officer, and other DoD stakeholders, underscoring that the program is managed with an emphasis on measurable progress and real-world relevance.

From an administrative standpoint, the funding opportunity is issued by the Department of Defense, Department of the Army, through USAMRAA under Funding Opportunity Number W81XWH-20-PRMRP-FPA. It supports science and technology and other research and development activities (CFDA 12.420) and allows either cooperative agreements or grants. Eligibility is described as unrestricted (open to any entity type), subject to any additional clarifications in the full notice. For this FY20 cycle, the posting indicated an expected total of four awards. The original opportunity dates show it was created on February 28, 2020, with an original closing date of August 6, 2020. The public listing shows an award ceiling of 0, which typically indicates that applicants must rely on the full program announcement for budget limits or that ceilings may be managed through other documentation rather than the summary field.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "CDMRP Peer Reviewed Medical Research Program Focused Program Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Feb 28, 2020.
• Applicants must submit their applications by Aug 06, 2020. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 4 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 20 PRMRP FPA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: